p09-10. impact of ctl escape mutations in hiv-1 nef on viral replication

1
BioMed Central Page 1 of 1 (page number not for citation purposes) Retrovirology Open Access Poster presentation P09-10. Impact of CTL escape mutations in HIV-1 Nef on viral replication C Oniangue-Ndza* 1 , A Schneidewind 1 , MA Brockman 1 , ZL Brumme 1 , CL Boutwell 1 , YE Wang 1 , CJ Brumme 1 , KA Power 1 , AD Gladden 1 , M Kemper 1 , S Le Gall 1 , H Streeck 1 , G Alter 1 , M Altfeld 1 , D Heckerman 2 , BD Walker 1 and TM Allen 1 Address: 1 Ragon Institute of MGH, MIT and Harvard (formerly PARC), Charlestown, USA and 2 eScience Research Group, Microsoft Research, Redmond, WA, USA * Corresponding author Background HIV-1 Nef is a multifunctional protein frequently targeted by host CD8+ T cell responses in early and chronic phases of HIV-1 infection. In vivo reversions of CTL escape muta- tions within Nef have been reported, suggesting a possible impact of immune-selected mutations in Nef on viral fit- ness. The goal of this work was to determine whether CD8+ T cell selected mutations in regions outside of Gag, such as in Nef, also impair viral replication and may thus contribute to early immune control of HIV-1. Methods A set of 13 HLA class I-associated amino acid polymor- phisms located in the central conserved region of Nef were engineered into HIV-1 strain NL4-3 and viral replication was assayed using a CEM-GFP reporter cell line. CD4 and MHC-I down regulation were measured by flow cytome- try. Results While the majority of the analyzed polymorphisms had little to no effect on viral replication capacity (RC), two mutations (K94E and H116N) residing within the immu- nodominant CD8 epitopes B08-FL8 and B57-HW9 caused significant reductions in replication capacity of NL4-3 (RC = 0.83, P = 0.0026 and 0.85, P = 0.02, respec- tively using Student's t-test). These two mutations also reduced the ability of NL4-3 to down regulate CD4 surface expression but did not alter MHC-I down-regulation. Notably, both of these mutations are located adjacent to or within the well-conserved region of Nef essential for efficient down-regulation of CD4 (residues 96 to 144). Conclusion These data suggest that particular CTL immune-selected mutations within functional domains of Nef can impair the replication capacity of HIV-1, and thus may be con- tributing to the ability of particular CD8+ T cell responses to mediate early control of HIV-1 by causing reductions in viral fitness. from AIDS Vaccine 2009 Paris, France. 19–22 October 2009 Published: 22 October 2009 Retrovirology 2009, 6(Suppl 3):P123 doi:10.1186/1742-4690-6-S3-P123 <supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement> This abstract is available from: http://www.retrovirology.com/content/6/S3/P123 © 2009 Oniangue-Ndza et al; licensee BioMed Central Ltd.

Upload: cl-boutwell

Post on 12-Dec-2016

214 views

Category:

Documents


2 download

TRANSCRIPT

BioMed Central

Page 1 of 1(page number not for citation purposes)

Retrovirology

Open AccessPoster presentationP09-10. Impact of CTL escape mutations in HIV-1 Nef on viral replicationC Oniangue-Ndza*1, A Schneidewind1, MA Brockman1, ZL Brumme1, CL Boutwell1, YE Wang1, CJ Brumme1, KA Power1, AD Gladden1, M Kemper1, S Le Gall1, H Streeck1, G Alter1, M Altfeld1, D Heckerman2, BD Walker1 and TM Allen1

Address: 1Ragon Institute of MGH, MIT and Harvard (formerly PARC), Charlestown, USA and 2eScience Research Group, Microsoft Research, Redmond, WA, USA

* Corresponding author

BackgroundHIV-1 Nef is a multifunctional protein frequently targetedby host CD8+ T cell responses in early and chronic phasesof HIV-1 infection. In vivo reversions of CTL escape muta-tions within Nef have been reported, suggesting a possibleimpact of immune-selected mutations in Nef on viral fit-ness. The goal of this work was to determine whetherCD8+ T cell selected mutations in regions outside of Gag,such as in Nef, also impair viral replication and may thuscontribute to early immune control of HIV-1.

MethodsA set of 13 HLA class I-associated amino acid polymor-phisms located in the central conserved region of Nef wereengineered into HIV-1 strain NL4-3 and viral replicationwas assayed using a CEM-GFP reporter cell line. CD4 andMHC-I down regulation were measured by flow cytome-try.

ResultsWhile the majority of the analyzed polymorphisms hadlittle to no effect on viral replication capacity (RC), twomutations (K94E and H116N) residing within the immu-nodominant CD8 epitopes B08-FL8 and B57-HW9caused significant reductions in replication capacity ofNL4-3 (RC = 0.83, P = 0.0026 and 0.85, P = 0.02, respec-

tively using Student's t-test). These two mutations alsoreduced the ability of NL4-3 to down regulate CD4 surfaceexpression but did not alter MHC-I down-regulation.Notably, both of these mutations are located adjacent toor within the well-conserved region of Nef essential forefficient down-regulation of CD4 (residues 96 to 144).

ConclusionThese data suggest that particular CTL immune-selectedmutations within functional domains of Nef can impairthe replication capacity of HIV-1, and thus may be con-tributing to the ability of particular CD8+ T cell responsesto mediate early control of HIV-1 by causing reductions inviral fitness.

from AIDS Vaccine 2009Paris, France. 19–22 October 2009

Published: 22 October 2009

Retrovirology 2009, 6(Suppl 3):P123 doi:10.1186/1742-4690-6-S3-P123

<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>

This abstract is available from: http://www.retrovirology.com/content/6/S3/P123

© 2009 Oniangue-Ndza et al; licensee BioMed Central Ltd.